
Full name:Alnylam Pharmaceuticals, Inc.;
Full Address:300 Third Street 3rd Floor Cambridge, MA 02142 United States 617-551-8200 http://www.alnylam.com;
Sector:Healthcare;
Industry:Biotechnology;
Market Cap: 11.72B;

Description:
 Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeuticsbased on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines,cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran,which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, aninvestigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleedingdisorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinicalprograms include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment ofcomplement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutictargeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis Bvirus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The MedicinesCompany; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of BritishColumbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in2002 and is headquartered in Cambridge, Massachusetts.;

Fiscal Year:2016;
Total Revenue:47159;
Net Revenue:-410108;
Total Assets:1262810;

Fiscal Year:2015;
Total Revenue:41097;
Net Revenue:-290073;
Total Assets:1386510;

Fiscal Year:2014;
Total Revenue:50561;
Net Revenue:-360395;
Total Assets:1079595;


